Thor Halfdanarson, Professor of Oncology at Mayo Clinic School of Medicine, shared a post on X:
“Genomic/transcriptomic alterations in advanced NENs
168 patients with advanced, treatment-refractory NENs. Whole genome/exome and RNA seq.
Too much info to detail here and perhaps not a whole lot of ned data but NGS can lead to revised diagnosis such as in the cases of EWSR1 fusions. Also, almost 10% have germline alterations.
86% of patients received molecularly guided therapy recommendations but I find that to be very high and and I think we need to be clear on what is truly actionable and relevant in this disease. Benefit was also seen in those who had such therapy but then, benefit is often seen in those who have empiric later-lines therapy.
That all said, an excellent addition to the literature.”
Title: Clinically actionable genomic and transcriptomic landscape of advanced neuroendocrine neoplasms
Authors: Simon Kreutzfeldt, Leonidas Apostolidis, Małgorzata Oleś, Eva Krieghoff-Henning, Christoph E. Heilig, Christoph Heining, Andreas Mock, Maria-Veronica Teleanu, Barbara Hutter, Laura Gieldon, Barbara Klink, Katja Beck, Daniela Richter, Annika Baude-Müller, Eva Reisinger, Nils Hammer, Leila Kamkar, Katrin Pfütze, Christina Geörg, Mario Lamping, Damian T. Rieke, Sebastian Uhrig, Henning Jann, Ulrich-Frank Pape, Michael Allgäuer, Albrecht Stenzinger, Eva C. Winkler, Bertram Wiedenmann, Dirk Jäger, Benedikt Brors, Daniel Hübschmann, Evelin Schröck, Ulrich Keilholz, Marianne Pavel, Peter Horak, Hanno Glimm, Stefan
Other Articles Featuring Thor Halfdanarson on OncoDaily.
